Tags

Type your tag names separated by a space and hit enter

Gabapentin for the treatment of pain in guillain-barré syndrome: a double-blinded, placebo-controlled, crossover study.
Anesth Analg. 2002 Dec; 95(6):1719-23, table of contents.A&A

Abstract

Pain syndromes of Guillain-Barré are neuropathic as well as nociceptive in origin. We aimed to evaluate the therapeutic efficacy of gabapentin in relieving the bimodal nature of pain in Guillain-Barré syndrome in a randomized, double-blinded, placebo-controlled, crossover study in 18 patients admitted to the intensive care unit for ventilatory support. Patients were assigned to receive either gabapentin (15 mg. kg(-1). d(-1) in 3 divided doses) or matching placebo as initial medication for 7 days. After a 2-day washout period, those who previously received gabapentin received placebo, and those previously receiving placebo received gabapentin as in the initial phase. Fentanyl 2 micro g/kg was used as a rescue analgesic on patient demand or when the pain score was >5 on a numeric rating scale of 0-10. The numeric rating score, sedation score, consumption of fentanyl, and adverse effects were noted, and these observed variables were compared. The numeric pain score decreased from 7.22 +/- 0.83 to 2.33 +/- 1.67 on the second day after initiation of gabapentin therapy and remained low during the period of gabapentin therapy (2.06 +/- 0.63) (P < 0.001). There was a significant decrease in the need for fentanyl from Day 1 to Day 7 during the gabapentin therapy period (211.11 +/- 21.39 to 65.53 +/- 16.17 [ micro g]) in comparison to the placebo therapy period (319.44 +/- 25.08 to 316.67 +/- 24.25 [ micro g]) (P < 0.001).

IMPLICATIONS

Gabapentin, an antiepileptic drug, has been used effectively for different types of pain management. This study demonstrates that gabapentin has minimal side effects and is an alternative to opioids and nonsteroidal antiinflammatory drugs for management of the bimodal nature of pain of Guillain-Barré Syndrome patients.

Authors+Show Affiliations

Department of Anaesthesiology and Critical Care Medicine, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. ckpandey@sgpgi.ac.inNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

12456446

Citation

Pandey, Chandra K., et al. "Gabapentin for the Treatment of Pain in Guillain-barré Syndrome: a Double-blinded, Placebo-controlled, Crossover Study." Anesthesia and Analgesia, vol. 95, no. 6, 2002, 1719-23, table of contents.
Pandey CK, Bose N, Garg G, et al. Gabapentin for the treatment of pain in guillain-barré syndrome: a double-blinded, placebo-controlled, crossover study. Anesth Analg. 2002;95(6):1719-23, table of contents.
Pandey, C. K., Bose, N., Garg, G., Singh, N., Baronia, A., Agarwal, A., Singh, P. K., & Singh, U. (2002). Gabapentin for the treatment of pain in guillain-barré syndrome: a double-blinded, placebo-controlled, crossover study. Anesthesia and Analgesia, 95(6), 1719-23, table of contents.
Pandey CK, et al. Gabapentin for the Treatment of Pain in Guillain-barré Syndrome: a Double-blinded, Placebo-controlled, Crossover Study. Anesth Analg. 2002;95(6):1719-23, table of contents. PubMed PMID: 12456446.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Gabapentin for the treatment of pain in guillain-barré syndrome: a double-blinded, placebo-controlled, crossover study. AU - Pandey,Chandra K, AU - Bose,Neeta, AU - Garg,Garima, AU - Singh,Namita, AU - Baronia,Arvind, AU - Agarwal,Anil, AU - Singh,Prabhat K, AU - Singh,Uttam, PY - 2002/11/29/pubmed PY - 2003/1/3/medline PY - 2002/11/29/entrez SP - 1719-23, table of contents JF - Anesthesia and analgesia JO - Anesth Analg VL - 95 IS - 6 N2 - UNLABELLED: Pain syndromes of Guillain-Barré are neuropathic as well as nociceptive in origin. We aimed to evaluate the therapeutic efficacy of gabapentin in relieving the bimodal nature of pain in Guillain-Barré syndrome in a randomized, double-blinded, placebo-controlled, crossover study in 18 patients admitted to the intensive care unit for ventilatory support. Patients were assigned to receive either gabapentin (15 mg. kg(-1). d(-1) in 3 divided doses) or matching placebo as initial medication for 7 days. After a 2-day washout period, those who previously received gabapentin received placebo, and those previously receiving placebo received gabapentin as in the initial phase. Fentanyl 2 micro g/kg was used as a rescue analgesic on patient demand or when the pain score was >5 on a numeric rating scale of 0-10. The numeric rating score, sedation score, consumption of fentanyl, and adverse effects were noted, and these observed variables were compared. The numeric pain score decreased from 7.22 +/- 0.83 to 2.33 +/- 1.67 on the second day after initiation of gabapentin therapy and remained low during the period of gabapentin therapy (2.06 +/- 0.63) (P < 0.001). There was a significant decrease in the need for fentanyl from Day 1 to Day 7 during the gabapentin therapy period (211.11 +/- 21.39 to 65.53 +/- 16.17 [ micro g]) in comparison to the placebo therapy period (319.44 +/- 25.08 to 316.67 +/- 24.25 [ micro g]) (P < 0.001). IMPLICATIONS: Gabapentin, an antiepileptic drug, has been used effectively for different types of pain management. This study demonstrates that gabapentin has minimal side effects and is an alternative to opioids and nonsteroidal antiinflammatory drugs for management of the bimodal nature of pain of Guillain-Barré Syndrome patients. SN - 0003-2999 UR - https://www.unboundmedicine.com/medline/citation/12456446/Gabapentin_for_the_treatment_of_pain_in_guillain_barré_syndrome:_a_double_blinded_placebo_controlled_crossover_study_ L2 - https://doi.org/10.1097/00000539-200212000-00046 DB - PRIME DP - Unbound Medicine ER -